Homepage > Company > Media > Pharma News > 2019 > China regulator approves imports of J&J's Tremfya

China regulator approves imports of J&J's Tremfya

BEIJING (Reuters) - China has approved imports of Johnson & Johnson’s Tremfya (guselkumab), the National Medical Products Administration said in a notice on Friday.

The drug will be used to treat moderate to severe plaque psoriasis in adults who are suitable for systemic therapy, the administration said.

J&J is positioning Tremfya as a better alternative to Novartis’s Cosentyx as it seeks to take market share away from the treatment, which was launched two years ago and is among the top-selling treatments in the $11 billion global psoriasis market.

DECEMBER 27, 2019

https://www.reuters.com/

Read also

New therapy from UI Health

New therapy from UI Health becomes the first FDA-approved treatment for brittle type 1 diabetes

FDA Probes Potential

FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy

BeiGene’s

BeiGene’s Tevimbra approved by EC for first-line gastric and oesophageal cancer use

Applied Therapeutics Stock Plummets After FDA Rejects Metabolic Disease Drug

Applied Therapeutics' application for a treatment of a rare metabolic disease was rejected by the Food and Drug Administration. The FDA said the drug, govorestat for galactosemia, had "defici...